Ista Pharmaceuticals (ISTA) Inactive 10-Q2003 Q3 Quarterly report

Filed: 21 Oct 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: abstaining, Academy, acid, advertise, advertising, agency, Akorn, American, aminocaproic, anterior, appointment, arrangement, attaching, authorization, await, billion, block, blurring, broker, cancellation, cataract, chamber, chronic, classified, commonly, complex, confirm, cornea, Cosmetic, DEA, dispute, domestic, duly, educational, Ernst, factor, fashion, frame, gel, global, gradually, hand, IMS, Internet, introduction, label, labeling, launch, launched, lesser, LLP, longer, maleate, matter, Medical, Milliman, NDC, opportunistic, opportunity, orphan, packing, Pfizer, plant, prescription, privilege, promote, promotion, promotional, published, ratified, reformulation, release, retain, revoking, scientific, serve, shareholder, shipping, short, solution, space, sponsored, storing, successor, supplemental, targeted, trauma, unique, uniquely, unwilling, usage, widely, Wilkerson, Xibrom, Young

Removed: application, assumed, bromfenac, CIBA, combined, commenced, corporate, decrease, enable, fourth, front, fully, funding, goal, identifying, incurring, initiating, integrated, lead, marketplace, Medicine, Mexico, month, recent, recently, stockholder, subsidiary, wholly, work

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ISTA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Vicente Anido, Jr., Ph.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of ISTA Pharmaceuticals, Inc. on Form 10-Q for the quarterly period ended September 30, 2003 fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q for the period ended September 30, 2003 fairly presents in all material respects the financial condition and results of operations of ISTA Pharmaceuticals, Inc.

Date: October 20, 2003

/s/ Vicente Anido, Jr., Ph.D.

Vicente Anido, Jr., Ph.D.

President and Chief Executive Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.